Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T60c in advanced solid tumors
NCT06082557Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2023
- Primary completion
- Mar 2025
- Modality
- CAR-T Cells
01
Overview
Phase 2, open-label, single-arm trial of autologous TROP2-CAR-transduced PD-1-positive T cells T60c in solid tumor, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Objective Response Rate at 3 months and Disease Control Rate at 3 months. Status: unknown.
02
Drugs
autologous TROP2-CAR-transduced PD-1-positive T cells T60c
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06082557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06082557.